Clinical trials have compared nebivolol at target dosages of 5 and 10 mg once daily with placebo and, in small trials, with carvedilol in the treatment of adults with chronic heart failure.

[62] After a 4-week placebo run-in period, patients were randomized to receive either placebo, nebivolol 1, 5 or 10 mg once daily, or HCTZ 12.5 or 25 mg once daily, or one of six possible ...